Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden · Delayed Price · Currency is SEK 7.77
-0.12 (-1.52%)
Sep 2, 2026, 5:29 PM CET
Egetis Therapeutics AB Cash Flow Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -405.4 | -342.5 | -343.6 | -326.9 | -193.8 | -104.5 |
Depreciation & Amortization | 10.5 | 3.8 | 3.4 | 3.6 | 2.7 | 2.5 |
Other Amortization | 33.7 | 33.7 | - | - | - | - |
Stock-Based Compensation | 13.4 | 13.4 | 14.7 | 8 | 8.8 | 1.2 |
Other Operating Activities | 14.5 | -1.8 | 9 | 6 | -2.1 | -1.1 |
Change in Accounts Receivable | 30.1 | -8.6 | 13.4 | -22.9 | -10.7 | 3.1 |
Change in Other Net Operating Assets | 3.1 | 35 | 75.2 | 53.8 | 21.6 | -31.3 |
Operating Cash Flow | -300.1 | -267 | -227.9 | -278.4 | -173.5 | -130.1 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | 0.5 | - | - | - | - | -0.2 |
Cash Acquisitions | -1.7 | -1.3 | -1.2 | - | -1.7 | -5 |
Sale (Purchase) of Intangibles | -1.5 | -1.5 | - | - | - | - |
Investment in Securities | - | - | - | - | - | -0.8 |
Investing Cash Flow | -2.7 | -2.8 | -1.2 | - | -1.7 | -6 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | - | - | - | 108.8 | - | - |
Long-Term Debt Repaid | - | -31.9 | -10.2 | -5.6 | -9.1 | -8.9 |
Net Debt Issued (Repaid) | -33.4 | -31.9 | -10.2 | 103.2 | -9.1 | -8.9 |
Issuance of Common Stock | 533.2 | 183.2 | 301.5 | 381.9 | 177.4 | - |
Repurchase of Common Stock | - | - | -1.5 | - | - | - |
Other Financing Activities | -25.8 | -11.3 | -18.9 | -26.2 | -12.6 | - |
Financing Cash Flow | 474 | 140 | 270.9 | 458.9 | 155.7 | -8.9 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | 4.7 | -5.4 | 5.8 | -4.8 | 3.2 | 1.1 |
Miscellaneous Cash Flow Adjustments | -0.1 | - | 0.1 | - | - | - |
Net Cash Flow | 175.8 | -135.2 | 47.7 | 175.7 | -16.3 | -143.9 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -299.6 | -267 | -227.9 | -278.4 | -173.5 | -130.3 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -453.94% | -427.89% | -494.36% | -483.33% | -767.70% | -341.10% |
Free Cash Flow Per Share | -0.75 | -0.71 | -0.73 | -1.07 | -0.89 | -0.72 |
Levered Free Cash Flow | -148.8 | -139.65 | -105.43 | -159.79 | -112.39 | -90.55 |
Unlevered Free Cash Flow | -142.49 | -130.65 | -94.43 | -157.16 | -112.33 | -90.43 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 14.4 | 14.4 | 17.6 | 4.1 | 0.1 | - |
Cash Income Tax Paid | 0.6 | 0.5 | 0.3 | 0.1 | - | - |
Change in Working Capital | 33.2 | 26.4 | 88.6 | 30.9 | 10.9 | -28.2 |